3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2024.02.05
3003新葡的京集团:第六届董事会第八次会议决议公告
2024.02.05
3003新葡的京集团:关于深圳证监局对公司采取责令改正措施决定的整改报告
2024.01.31
3003新葡的京集团:关于对深圳交易所问询函回复的公告
2024.01.31
3003新葡的京集团:关于启动独立第三方调查的公告
2024.01.31
3003新葡的京集团:关于2023年度拟计提存货跌价准备的提示性公告
2024.01.31
3003新葡的京集团:2023年年度业绩预告
2024.01.16
3003新葡的京集团:关于收到深圳证监局监管关注函的公告
2024.01.15
3003新葡的京集团:关于子公司重要事项的公告
2024.01.10
3003新葡的京集团:2024年第一次临时股东大会决议公告
2023.12.19
3003新葡的京集团:关于联营公司君圣泰医药拟在香港联交所主板上市的公告
第一页
上一页
5
6
7
8
9
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.